JUNS · Jupiter Neurosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Revenue | $18.7K | - | - | - | - | - | - |
| Cost of Revenue | $4.4K | - | - | - | - | - | - |
| Gross Profit | $14.3K | - | - | - | - | - | - |
| R&D | $411.0K | - | $816.7K | $101.1K | $98.7K | - | $91.9K |
| SG&A | $1.57M | - | $1.48M | $1.51M | $472.0K | - | $401.6K |
| Total Operating Expenses | $1.98M | - | $2.30M | $557.1K | $570.7K | - | $493.5K |
| D&A | - | - | - | - | - | - | - |
| Operating Income | ($1.96M) | - | ($2.30M) | ($557.1K) | ($570.7K) | - | ($493.5K) |
| Interest Expense | $118.6K | - | $1.2K | $1.1K | $65.8K | - | $80.6K |
| Income Tax | - | - | - | - | - | - | - |
| Net Income | ($2.06M) | - | ($2.29M) | ($2.25M) | ($1.53M) | - | ($1.77M) |
| EPS - Basic | ($0.06) | - | ($0.07) | $0.01 | ($0.02) | - | ($0.07) |
| EPS - Diluted | ($0.06) | - | ($0.07) | $0.01 | ($0.02) | - | ($0.07) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.36M | $3.79M | $723.8K | $1.88M | $2.71M | $3.77M | $28.5K |
| Accounts Receivable | - | $2.6K | - | - | - | - | - |
| Inventory | $148.1K | $159.8K | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - |
| Current Assets | $3.41M | $4.82M | $1.63M | $2.82M | $3.61M | $4.65M | $514 |
| Total Assets | $3.95M | $5.56M | $2.58M | $3.97M | $4.96M | $6.20M | $148.6K |
| Current Liabilities | $6.73M | $7.40M | $2.52M | $2.63M | $1.89M | $2.01M | $5.68M |
| Long-term Debt | - | - | - | - | - | - | - |
| Total Liabilities | $6.73M | $7.40M | $2.52M | $2.63M | $1.90M | $2.03M | $5.84M |
| Stockholders' Equity | ($2.78M) | ($1.83M) | $57.4K | $1.34M | $3.06M | $4.17M | ($5.80M) |
| Retained Earnings | ($36.73M) | ($34.67M) | ($32.09M) | ($29.80M) | ($27.55M) | ($26.02M) | ($24.49M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.43M) | - | - | - | ($65.2K) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - |
| Financing Cash Flow | $5.5K | - | - | - | $45.0K | - | - |
| CapEx | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross margin | 76.6% | - | - | - | - | - | - |
| Operating margin | -10524.3% | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - |
| Net margin | -11054.9% | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - |
| R&D / Revenue | 2203.8% | - | - | - | - | - | - |
| SG&A / Revenue | 8397.2% | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - |
| Return on assets | -52.2% | - | -88.8% | -56.8% | -30.8% | - | -1194.0% |
| Return on equity | 74.1% | - | -3984.9% | -168.1% | -49.9% | - | 30.6% |
| Return on invested capital | - | - | - | - | - | - | - |
| Liquidity | |||||||
| Current ratio | 0.51 | 0.65 | 0.65 | 1.07 | 1.91 | 2.31 | 0.00 |
| Quick ratio | 0.48 | 0.63 | 0.65 | 1.07 | 1.91 | 2.31 | 0.00 |
| Cash ratio | 0.35 | 0.51 | 0.29 | 0.71 | 1.43 | 1.88 | 0.01 |
| Leverage | |||||||
| Debt / Equity | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Interest coverage | -16.6x | - | -1925.4x | -490.8x | -8.7x | - | -6.1x |
| Equity multiplier | -1.42 | -3.04 | 44.87 | 2.96 | 1.62 | 1.49 | -0.03 |
| Liabilities / Assets | 1.70 | 1.33 | 0.98 | 0.66 | 0.38 | 0.33 | 39.28 |
| Efficiency | |||||||
| Asset turnover | 0.00 | - | - | - | - | - | - |
| Inventory turnover | 0.03 | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - |
| Days inventory outstanding | 12390d | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - |
| Valuation | |||||||
| P / E | - | - | - | 102.0x | - | - | - |
| P / B | - | - | 1043.4x | 23.3x | 5.3x | - | - |
| P / S | 710.7x | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| Growth | |||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -244.0% | - | -365.4% | - | - | - | - |
| Net income growth (YoY) | -34.9% | - | -29.0% | - | - | - | - |
| EPS growth (YoY) | -200.0% | - | 0.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$21.8K totalPremium Nutritional Supplements$21.8K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing JUPITER NEUROSCIENCES against the 5 most active filers in the same SIC group.